Multicenter retrospective case series evaluates clinical outcomes of IL6R therapy in NMOSD and MOGAD, suggesting benefits for severe attacks.
To evaluate clinical and radiological outcomes of anti-IL6R therapy when used as add-on therapy for severe attacks in MOGAD and AQP4+ NMOSD.
No takes yet. Share an insight, caveat, or question.
Flanagan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: